Bergenia

by | Mar 21, 2018 | Bergenia

How Can We Help?
You are here:
< Back

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[2] It acts as a COX-2 inhibitor.[3]

Mavacoxib, along with several other COX-2 selective inhibitors, including celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[4][5]

References

  1. ^ "Trocoxil EPAR". European Medicines Agency. 22 September 2008. Retrieved 26 June 2024.
  2. ^ European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
  3. ^ Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, et al. (October 2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.{{cite journal}}: CS1 maint: overridden setting (link)
  4. ^ Langreth R (23 June 2003). "The Chemical Cobbler". Forbes.{{cite news}}: CS1 maint: overridden setting (link)
  5. ^ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. 52 (5). St. Louis Section, American Chemical Society: 2. May 2001. Archived from the original (PDF) on 15 April 2018.


Categories
Table of Contents